Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2025 09:51 ET | Source: Research and Markets

Bavencio (Avelumab) Markets, 2019-2024, 2024-2029F, 2034F

Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Bavencio (Avelumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...
December 04, 2023 08:00 ET | Source: Vaccinex, Inc.

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule

Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ...
September 28, 2023 21:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Pricing of $9.6 Million Public Offering

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
March 23, 2023 08:00 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference

ROCHESTER, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, “Vaccinex”), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
March 21, 2023 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

The study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade ...
May 17, 2021 08:15 ET | Source: Vaccinex, Inc.

Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update

Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical...
April 21, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research

ROCHESTER, N.Y., April 21, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
October 09, 2020 04:24 ET | Source: Research and Markets

Global Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast 20202030

Dublin, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The "Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been...
May 13, 2020 17:02 ET | Source: Vaccinex, Inc.

Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting

ROCHESTER, N.Y., May 13, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
April 27, 2020 07:45 ET | Source: Vaccinex, Inc.

Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting

ROCHESTER, N.Y., April 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...

Next Page keyboard_arrow_right